Logo

NABsys Buys Hybridization Company GeneSpectrum to Pursue $1,000 Genome

Dec 22, 2006
NEW YORK (GenomeWeb News) - NABsys, a next-generation sequencing company based in Providence, RI, said today that it has purchased DNA hybridization company GeneSpectrum in an all-stock transaction.
 
NABsys said it will combine GeneSpectrum's probe design and hybridization techniques with its nanopore-based technology, which it has licensed from Brown University, to sequence human DNA at dramatically cheaper rates.
 
NABsys said its goal is to reduce the cost of sequencing a human genome from its current level of $10 million to $1,000 per genome, which the company said would take DNA sequencing from the research lab to the doctor's office.
 
Financial terms of the agreement were not disclosed.
 
John Oliver, co-founder of GeneSpectrum, has been appointed vice president of R&D at NABsys.

Filed under

Clinical Sequencing
Sequencing
Breaking News
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.